Gene Elimination in Tregs Triggers Lifelong Anticancer Response in Mice
Scientists at Baylor College of Medicine have discovered a crucial regulator of the anticancer immune response that could point to the development of new approaches to fight cancer. Reported in PNAS, the team’s research showed that in animal models of breast and prostate cancer, eliminating the gene SRC-3 specifically in a type of immune cell called regulatory T cells (Tregs) triggered a lifelong anticancer response that eradicated the tumor without the typical side effects observed with other therapies.
The research also showed that transferring Tregs without SRC-3 to animals carrying breast cancer tumors resulted in long-term elimination of the tumor without negative side effects.
Tregs play an essential role in restraining immune responses to maintain immune homeostasis and prevent autoimmune disease, and are of great interest from an anticancer therapeutic perspective, the authors explained. “Tregs play a critical role in cancer progression by generating an immune-suppressive microenvironment and thus have been a major focus for immune checkpoint inhibitor therapeutic development.”
ارسال به دوستان